CD8A and breast carcinoma: Notably, depletion of DCs (Fig. 6A and B, Fig. S7A) significantly blocked the antitumor effects of HELA-Exos in breast cancer (Fig. 6C-E), as well as its active effects on CD8+ T cells (Fig. 6F-H, Fig. S7B) within the TME.